Company Description
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.
The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and α7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.
The company is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Lloyd Blair Jordan L.L.B., M.B.A. |
Contact Details
Address: 3000 El Camino Real, Bldg 4, Ste 200 Palo Alto, California 94306 United States | |
| Phone | 650-507-0669 |
| Website | 180lifesciences.com |
Stock Details
| Ticker Symbol | ATNF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | 68236V104 |
| ISIN Number | US68236V3024 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James N. Woody M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder and Executive Chairman |
| Ozan Pamir C.F.A. | Chief Financial Officer and Secretary |
| Dr. Jonathan B. Rothbard Ph.D. | Chief Scientific Officer |
| Prof. Jagdeep Nanchahal | Co-Founder and Chairman of Clinical Advisory Board |
| Jason Assad | Director of IR |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 2, 2024 | 8-K | Current Report |
| May 21, 2024 | 8-K | Current Report |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 29, 2024 | 10-K/A | [Amend] Annual report |
| Apr 24, 2024 | EFFECT | Notice of Effectiveness |
| Apr 24, 2024 | EFFECT | Notice of Effectiveness |
| Apr 22, 2024 | POS AM | Post-Effective amendments for registration statement |